Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Long-Term Deferred Tax (2020 - 2025)

Historic Long-Term Deferred Tax for China Pharma Holdings (CPHI) over the last 10 years, with Q3 2025 value amounting to $22.7 million.

  • China Pharma Holdings' Long-Term Deferred Tax changed N/A to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year change of. This contributed to the annual value of $21.7 million for FY2024, which is 78.48% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Long-Term Deferred Tax is $22.7 million.
  • In the past 5 years, China Pharma Holdings' Long-Term Deferred Tax ranged from a high of $24.0 million in Q4 2021 and a low of $21.5 million during Q4 2023
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $22.0 million (2022), whereas its average is $22.3 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first plummeted by 1331.78% in 2021, then soared by 78.48% in 2024.
  • China Pharma Holdings' Long-Term Deferred Tax (Quarter) stood at $24.0 million in 2021, then fell by 8.33% to $22.0 million in 2022, then fell by 2.07% to $21.5 million in 2023, then increased by 0.78% to $21.7 million in 2024, then grew by 4.61% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $22.1 million for Q2 2025, and $21.9 million during Q1 2025.